Antisense & RNAi Therapeutics Market Size & Forecast Report, 2014 - 2025

Global Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain the functions of genes or therapeutic efforts. Antisense molecules are termed synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi).

Double-stranded RNA fragments initiate the RNAi process, and this double helix is the actual suppressor of its equivalent gene. The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.

Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come. However, the toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years. Antisense & RNAi Therapeutics Market is segmented based on technology, mode of action, application, and region.

Antisense RNA and RNA Interference are the enhanced technology used that could be explored in Antisense & RNAi Therapeutics in the forecast period. RNA interference includes miRNA and siRNA. RNA Interference technology accounted for the largest market share and is estimated to lead the overall market in the coming years. This may be because of the advantages of the technology over antisense technology. The miRNA maintains the identity of the cell; whereas siRNA allows induction at enhanced stages of cancer growth.

The mode of action comprises topical delivery, pulmonary delivery, intraperitoneal injections, intravenous injections, intradermal injections, and others that could be explored in Antisense & RNAi Therapeutics in the foremost period. The intravenous route sector accounts for the largest market share and is estimated to lead the overall market in the coming years. This may be because the liver can be targeted easily under an intravenous and fast drug removal without anticipated pharmacological action.

The market may be categorized based on applications like infectious diseases, oncology, genetic disorders, cardiovascular, neurodegenerative disorders, respiratory disorders, renal diseases, and others. The oncology sector accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years.

Globally, North America accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be the growing number of clinical trials, government initiatives for developing antisense therapeutics, developed research and development laboratories, and high investment by biotechnology industries for the development of RNAi therapeutics. The United States is a major consumer of Antisense & RNAi Therapeutics in this region, as the presence of key manufacturers in the region.

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on future growth. Europe is the second-largest region with a significant market share. However, Asia Pacific is estimated to grow at the fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise government initiative toward R&D and various other forms of siRNA delivery techniques is a strong factor.

The key players of the Antisense & RNAi Therapeutics industry are Benitec Biopharma, GSK, Marina Biosciences, Sanofi-Genzyme, and Alnylam Pharmaceuticals. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

Market Segment:

Antisense & RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2014 - 2025)
    • RNA Interference
        • siRNA
        • miRNA
    • Antisense RNA

Antisense & RNAi Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)
    • Oncology
    • Cardiovascular
    • Respiratory Disorders
    • Renal Diseases
    • Neurodegenerative Disorders
    • Genetic Disorders
    • Infectious Diseases
    • Other

Antisense & RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)
    • Pulmonary Delivery
    • Intravenous Injections
    • Intradermal Injections
    • Intraperitoneal Injections
    • Topical Delivery
    • Other Delivery Methods

Antisense & RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
        • the U.S.
        • Canada
    • Europe
        • Germany
        • the U.K.
    • the Asia Pacific
        • Japan
        • China
    • Latin America
        • Brazil
    • Middle East & Africa
        • South Africa